search
Back to results

Minocycline for Alcohol Use Disorder

Primary Purpose

Alcohol Use Disorder, Inflammation, Neurocognitive Dysfunction

Status
Withdrawn
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Minocycline
Sugar pill
Sponsored by
University of California, Los Angeles
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcohol Use Disorder focused on measuring Minocycline

Eligibility Criteria

21 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Ages 25 - 45
  2. Meet DSM-5 diagnostic criteria for an AUD [n.b., only participants with moderate or severe AUD will be enrolled]
  3. Drink ≥ 48 standard drinks in a 30-day period before enrollment

Exclusion Criteria:

  1. Currently in treatment for AUD, a history of treatment in the 30 days before enrollment, or currently treatment seeking
  2. Current (last 12 months) DSM-V diagnosis of substance use disorder for any psychoactive substances other than alcohol and nicotine
  3. Lifetime DSM-V diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder
  4. Positive urine screen for narcotics, amphetamines, or sedative hypnotics
  5. Serious alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised
  6. Pregnancy, nursing, or refusal to use reliable method of birth control (if female)
  7. A medical condition that may interfere with safe study participation (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes)
  8. AST, ALT, or GGT ≥ 3 times upper normal limit
  9. Attempted suicide in the past 3 years and/or serious suicidal intention or plan within the past year
  10. Currently on prescription medication that contraindicates use of MINO
  11. Any other circumstances that, in the opinion of the investigators, compromises participant safety.
  12. Claustrophobia
  13. Participating in any other research study involving exposure to ionizing radiation in the past year will be excluded if the total cumulative exposure from the past research studies and the current research study would exceed the limits set by the FDA in 21 CFR 361.1. Specifically, the total cumulated dose to the whole body, active blood-forming organs, lens of the eye, and gonads must remain below 5 rems, and the cumulated dose to all other organs must remain below 15 rems. Potential participants who have had exposure to ionizing radiation in the past year will not be allowed to participate if we are unable to obtain proper documentation quantifying the amount of past exposure.
  14. Presence of a metal device in the body (e.g., pacemaker, infusion pump, aneurysm clip, metal prosthesis or plate): Those devices could either interfere with the acquisition of the MRI scan of the brain or for whom the MRI scan would pose a potential risk. If participants have a non-removable device in their body, they must acquire and show a document exhibiting the device is MRI-compatible.
  15. low affinity rs6971 genotype

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Minocycline

    Sugar Pill

    Arm Description

    200 mg/day

    Matched placebo

    Outcomes

    Primary Outcome Measures

    Microglial Activation
    Level of [11C]DAA1106 binding during PET imaging
    Cue-Induced Alcohol Craving
    Alcohol Urge Questionnaire (AUQ)
    Alcohol consumption
    Total drinks consumed
    Verbal Learning and Memory
    Hopkins Verbal Learning Test
    Set-Shifting
    Wisconsin Card Sorting Test
    Response Inhibition
    Stop Signal Task
    Manipulative Dexterity
    Grooved Pegboard Test
    Executive Function
    Digit Symbol Substitution Test
    Memory
    Digit Span
    Vocabulary
    WAIS Vocabulary
    Executive Function
    Rey Complex Figure Copy

    Secondary Outcome Measures

    Peripheral Proinflammatory Marker levels
    Serum level of cytokines and innate immune receptors
    Alcohol Use Disorder Severity
    Symptom count from the alcohol module for the Structured Clinical Interview for DSM-5

    Full Information

    First Posted
    July 28, 2017
    Last Updated
    January 22, 2019
    Sponsor
    University of California, Los Angeles
    Collaborators
    National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03244592
    Brief Title
    Minocycline for Alcohol Use Disorder
    Official Title
    Development of Minocycline as a Neuroimmune Therapy for Alcohol Use Disorder
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2019
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Investigator left institution prior to enrollment of study participants
    Study Start Date
    January 15, 2018 (Anticipated)
    Primary Completion Date
    March 1, 2018 (Actual)
    Study Completion Date
    March 1, 2018 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of California, Los Angeles
    Collaborators
    National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    Yes
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment. This study has important clinical implications, as the available treatments for alcohol use disorder are only modestly effective and testing novel medications is a high research priority.
    Detailed Description
    The research objective of this project is to advance medication development for AUD by conducting a randomized, double blind, placebo-controlled, neuroimaging study to examine the effects of minocycline on neuroinflammation, alcohol cue reactivity, neurocognitive performance, and alcohol use. In the proposed study, non-treatment seeking individuals with a current DSM-5 AUD diagnosis (N = 32) will be randomized to receive either 200 mg of minocycline per day or placebo for 28 days and complete two laboratory sessions. The first laboratory session will be performed immediately before commencing the medication regimen (day 0) and the second will be completed after taking the medication daily for 28 days. Within each laboratory session, participants will complete a cue reactivity paradigm, neurocognitive performance tasks, and a positron emission tomography (PET) imaging session. Neuroinflammation will be assessed by using PET imaging with the radiotracer N-(2,5-dimethoxy-benzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide, labeled with carbon-11 ([11C]-DAA1106), which binds to the mitochondrial translocator protein, a marker of activated microglia in brain. Additionally, blood samples will be drawn on days 0, 7, 14, 21, and 28 to measure circulating levels of proinflammatory markers and alcohol use over the four weeks of treatment will also be measured.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Alcohol Use Disorder, Inflammation, Neurocognitive Dysfunction, Craving, Alcohol Drinking
    Keywords
    Minocycline

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1, Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Masking Description
    Double Blind
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Minocycline
    Arm Type
    Active Comparator
    Arm Description
    200 mg/day
    Arm Title
    Sugar Pill
    Arm Type
    Placebo Comparator
    Arm Description
    Matched placebo
    Intervention Type
    Drug
    Intervention Name(s)
    Minocycline
    Intervention Description
    200 mg/day
    Intervention Type
    Drug
    Intervention Name(s)
    Sugar pill
    Other Intervention Name(s)
    Placebo
    Intervention Description
    Matched placebo
    Primary Outcome Measure Information:
    Title
    Microglial Activation
    Description
    Level of [11C]DAA1106 binding during PET imaging
    Time Frame
    Change from baseline after 28 days of medication dosing
    Title
    Cue-Induced Alcohol Craving
    Description
    Alcohol Urge Questionnaire (AUQ)
    Time Frame
    Change from baseline after 28 days of medication dosing
    Title
    Alcohol consumption
    Description
    Total drinks consumed
    Time Frame
    Day 28 of medication dosing period
    Title
    Verbal Learning and Memory
    Description
    Hopkins Verbal Learning Test
    Time Frame
    Change from baseline after 28 days of medication dosing
    Title
    Set-Shifting
    Description
    Wisconsin Card Sorting Test
    Time Frame
    Change from baseline after 28 days of medication dosing
    Title
    Response Inhibition
    Description
    Stop Signal Task
    Time Frame
    Change from baseline after 28 days of medication dosing
    Title
    Manipulative Dexterity
    Description
    Grooved Pegboard Test
    Time Frame
    Change from baseline after 28 days of medication dosing
    Title
    Executive Function
    Description
    Digit Symbol Substitution Test
    Time Frame
    Change from baseline after 28 days of medication dosing
    Title
    Memory
    Description
    Digit Span
    Time Frame
    Change from baseline after 28 days of medication dosing
    Title
    Vocabulary
    Description
    WAIS Vocabulary
    Time Frame
    Change from baseline after 28 days of medication dosing
    Title
    Executive Function
    Description
    Rey Complex Figure Copy
    Time Frame
    Change from baseline after 28 days of medication dosing
    Secondary Outcome Measure Information:
    Title
    Peripheral Proinflammatory Marker levels
    Description
    Serum level of cytokines and innate immune receptors
    Time Frame
    At baseline (day zero) and after 7, 14, and 21 and 28 days of medication dosing
    Title
    Alcohol Use Disorder Severity
    Description
    Symptom count from the alcohol module for the Structured Clinical Interview for DSM-5
    Time Frame
    At baseline (day zero) and after 28 days of medication dosing

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    21 Years
    Maximum Age & Unit of Time
    55 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Ages 25 - 45 Meet DSM-5 diagnostic criteria for an AUD [n.b., only participants with moderate or severe AUD will be enrolled] Drink ≥ 48 standard drinks in a 30-day period before enrollment Exclusion Criteria: Currently in treatment for AUD, a history of treatment in the 30 days before enrollment, or currently treatment seeking Current (last 12 months) DSM-V diagnosis of substance use disorder for any psychoactive substances other than alcohol and nicotine Lifetime DSM-V diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder Positive urine screen for narcotics, amphetamines, or sedative hypnotics Serious alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised Pregnancy, nursing, or refusal to use reliable method of birth control (if female) A medical condition that may interfere with safe study participation (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes) AST, ALT, or GGT ≥ 3 times upper normal limit Attempted suicide in the past 3 years and/or serious suicidal intention or plan within the past year Currently on prescription medication that contraindicates use of MINO Any other circumstances that, in the opinion of the investigators, compromises participant safety. Claustrophobia Participating in any other research study involving exposure to ionizing radiation in the past year will be excluded if the total cumulative exposure from the past research studies and the current research study would exceed the limits set by the FDA in 21 CFR 361.1. Specifically, the total cumulated dose to the whole body, active blood-forming organs, lens of the eye, and gonads must remain below 5 rems, and the cumulated dose to all other organs must remain below 15 rems. Potential participants who have had exposure to ionizing radiation in the past year will not be allowed to participate if we are unable to obtain proper documentation quantifying the amount of past exposure. Presence of a metal device in the body (e.g., pacemaker, infusion pump, aneurysm clip, metal prosthesis or plate): Those devices could either interfere with the acquisition of the MRI scan of the brain or for whom the MRI scan would pose a potential risk. If participants have a non-removable device in their body, they must acquire and show a document exhibiting the device is MRI-compatible. low affinity rs6971 genotype
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Daniel Roche, PhD
    Organizational Affiliation
    University of California, Los Angeles
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Minocycline for Alcohol Use Disorder

    We'll reach out to this number within 24 hrs